AB
Avicenna Biosciences utilizes a machine learning-driven medicinal chemistry platform to optimize drug candidates by rapidly identifying new chemical entities with improved potency and selectivity. This approach addresses the high failure rates in lead optimization due to off-target toxicity and poor pharmacokinetics, significantly reducing synthetic effort and development timelines.
Updated 4 months ago
Funding
$12.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Features
- Avicenna Biosciences utilizes a machine learning-driven medicinal chemistry platform to optimize drug candidates by rapidly identifying new chemical entities with improved potency and selectivity. This approach addresses the high failure rates in lead optimization due to off-target toxicity and poor pharmacokinetics, significantly reducing synthetic effort and development timelines.